Lola Reid= Am. #1

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, U6vA4CSqA3d0xeqZT7oicoNesxNZgg+/L6Br+BlvMc/Y3JnCknVyG3odvxtoKDBA yxRvyduenkwmEBoO6/nY1g== 0001193125-04-027691.txt : 20040223 0001193125-04-027691.hdr.sgml : 20040223 20040223104402 ACCESSION NUMBER: 0001193125-04-027691 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040223 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: INCARA PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0001261734 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 561953785 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79369 FILM NUMBER: 04620960 MAIL ADDRESS: STREET 1: PO BOX 14287 CITY: RTP STATE: NC ZIP: 27709-4287 FORMER COMPANY: FORMER CONFORMED NAME: INCARA INC DATE OF NAME CHANGE: 20030828 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: REID LOLA M CENTRAL INDEX KEY: 0001111002 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 3621 SWEETEN CREEK ROAD CITY: CHAPEL HILL STATE: NC ZIP: 27514 BUSINESS PHONE: 9194080942 MAIL ADDRESS: STREET 1: 3621 SWEETEN CREEK ROAD CITY: CHAPEL HILL STATE: NC ZIP: 27514 SC 13G/A 1 dsc13ga.htm LOLA REID= AM. #1 Lola Reid= Am. #1

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Incara Pharmaceuticals Corporation

(Name of Issuer)

Common Stock

(Title of Class of Securities)

45325 S-10-1

(CUSIP Numbers)

December 31, 2003

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.



1.		Name of Reporting Person I.R.S. Identification No. of above persons (entities only) Lola M. Reid

2.		Check the Appropriate Box if a Member of a Group (See Instructions) Not Applicable (a) ¨ (b) ¨

3.		SEC Use Only

4.		Citizenship or Place of Organization United States

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5. Sole Voting Power

427,986

6. Shared Voting Power

315,664

7. Sole Dispositive Power

427,986

8. Shared Dispositive Power

315,664


9.		Aggregate Amount Beneficially Owned by Each Reporting Person 743,650

10.		Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

11.		Percent of Class Represented by Amount in Row (9) 1.6%

12.		Type of Reporting Person (See Instructions) IN

Item 1

(a)

Name of Issuer

Incara Pharmaceuticals Corporation

Item 1

(b)

Address of Issuer’s Principal Executive Offices

79 T.W. Alexander Dr., 4401 Research Commons, Suite 200, P.O. Box 14287,

Research Triangle Park, NC 27709-4287

Item 2

(a)

Name of Person Filing

Lola M. Reid

Item 2

(b)

Address of Principal Business Office, or, if none, Residence

79 T.W. Alexander Dr., 4401 Research Commons, Suite 200, P.O. Box 14287,

Research Triangle Park, NC 27709-4287

Item 2

(c)

Citizenship

UnitedStates

Item 2

(d)

Title of Class of Securities:

CommonStock

Item 2

(e)

CUSIP Number:

45325 S-10-1

Item 3.

Filing pursuant to Rules 13d-1(b), or 13d-2(b)

Not Applicable

Item 4.

Ownership.

(a)

As of December 31, 2003, Dr. Reid beneficially owned an aggregate of 743,650 shares of the Issuer’s Common Stock which includes (i) 316,786 shares owned by Dr. Reid, (ii) 237,478 shares owned by Dr. Reid’s husband, (iii) 110,000 shares issuable upon exercise of options held by Dr. Reid, (iv) 78,186 shares issuable upon exercise of options held by Dr. Reid’s husband and (v) 1,200 shares issuable upon exercise of warrants held by Dr. Reid. Dr. Reid disclaims beneficial ownership of the shares held by her husband.

(b)

Percent of class: 1.6%. This final Schedule 13G is being filed because the ownership has decreased to less than 5% due to the issuance of additional shares of common stock by Incara Pharmaceuticals Corporation.

(c)

Number of shares as to which such person has:

(i)

Sole power to vote or to direct the vote: 427,986

(ii)

Shared power to vote or to direct the vote: 315,664

(iii)

Sole power to dispose or to direct the disposition of: 427,986

(iv)

Shared power to dispose or to direct the disposition of: 315,664

Item 5.

Ownership of Five Percent or Less of a Class

Not Applicable

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not Applicable

Item 8.

Identification and Classification of Members of the Group

Not Applicable

Item 9.

Notice of Dissolution of Group

Not Applicable

Item 10.

Certification

Not Applicable

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 17, 2004

Date

/s/ Lola M. Reid

Lola M. Reid

-----END PRIVACY-ENHANCED MESSAGE-----